Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer

Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer

Novel treatment regimens are required for castration-resistant prostate cancers (CRPCs) that become unresponsive to standard treatments, such as docetaxel and enzalutamide. Histone deacetylase (HDAC) inhibitors showed promising results in hematological malignancies, but they failed in solid tumors s...

Full description

Bibliographic Details
Main Authors: Zohaib Rana, Sarah Diermeier, Muhammad Hanif, Rhonda J. Rosengren
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Biomedicines
Subjects:
hdac inhibitors
histone deacetylases
epigenetics
prostate cancer
androgen receptor-negative
resistance mechanisms
Online Access:https://www.mdpi.com/2227-9059/8/2/22

Similar Items

Similar Items